Alice T. Shaw

ScholarGPS® ID: 53371863630600

Affiliation
Massachusetts General Hospital, Boston, United States
Affiliation History

Field
Medicine
Discipline
Oncology
Top Specialties
Cancer | Lung Cancer | Non-small-cell Lung Carcinoma | Thorax | Lymphoma | Mutation | Epidermal Growth Factor Receptor | Brain Metastasis | Chemotherapy | Neoplasm | Protein Kinase Inhibitor | Radiation Therapy | Tyrosine Kinase | Radiation | Tyrosine Kinase Inhibitor
Metrics Summary
Publication Count
328
Predicted Citations
53,067
Predicted h-index
100
Ranking

Publications and Citation History

Publications based on Top Specialties

Types of Publication

  • Publications
  • Books
  • Patents
  • NIH/NSF
You must register and claim your profile to add or remove publications from it.
... publications
FILTER BY:
Year
Type
Specialty
Affiliations
Access
Co-Authors
Add
Delete
Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK + non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study. (journal article)
Solomon, Benjamin J. | Liu, Geoffrey | Felip, Enriqueta | Mok, Tony S. K. | Soo, Ross Andrew | Mazieres, Julien | Shaw, Alice Tsang | de Marinis, Filippo | Goto, Yasushi | Wu, Yi-Long | ... | Bauer, Todd Michael
Journal of Clinical Oncology, volume 42, issue 17_suppl, pages LBA8503-LBA8503 (2024).
10.1200/JCO.2024.42.17_suppl.LBA8503
Cite | Source
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study (journal article)
Solomon, Benjamin J. | Liu, Geoffrey | Felip, Enriqueta | Mok, Tony S.K. | Soo, Ross A. | Mazieres, Julien | Shaw, Alice T. | de Marinis, Filippo | Goto, Yasushi | Wu, Yi-Long | ... | Bauer, Todd M.
Journal of Clinical Oncology (2024).
10.1200/JCO.24.00581
Cited by (10) | Cite | Source
Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer (journal article)
Chen, Joseph | Bearz, Alessandra | Kim, Dong-Wan | Mamdani, Hirva | Bauman, Jessica | Chiari, Rita | Ou, Sai-Hong Ignatius | Solomon, Benjamin J. | Soo, Ross A. | Felip, Enriqueta | ... | Pithavala, Yazdi K.
Clinical Pharmacokinetics, volume 63, issue 2, pages 171-182 (2024).
10.1007/s40262-023-01309-4
Cite | Source
Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations (journal article)
Bearz, Alessandra | Martini, Jean-François | Jassem, Jacek | Kim, Sang-We | Chang, Gee-Chen | Shaw, Alice T. | Shepard, Deborah A. | Dall’O’, Elisa | Polli, Anna | Thurm, Holger | ... | Solomon, Benjamin J.
Journal of Thoracic Oncology, volume 18, issue 11, pages 1581-1593 (2023).
10.1016/j.jtho.2023.07.023
Cited by (12) | Cite | Source
Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC (journal article)
Soo, Ross A. | Martini, Jean-François | van der Wekken, Anthonie J. | Teraoka, Shunsuke | Ferrara, Roberto | Shaw, Alice T. | Shepard, Deborah | Calella, Anna Maria | Polli, Anna | Toffalorio, Francesca | ... | Solomon, Benjamin J.
Journal of Thoracic Oncology, volume 18, issue 11, pages 1568-1580 (2023).
10.1016/j.jtho.2023.05.021
Cited by (14) | Cite | Source
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer (journal article)
Solomon, Benjamin J | Bauer, Todd M | K Mok, Tony S | Liu, Geoffrey | Mazieres, Julien | Marinis, Filippo de | Goto, Yasushi | Kim, Dong-Wan | Wu, Yi-Long | Jassem, Jacek | ... | Felip, Enriqueta
Future Oncology, volume 19, issue 14, pages 961-973 (2023).
10.2217/fon-2022-1289
Cite | Source
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study (journal article)
Solomon, Benjamin J | Bauer, Todd M | Mok, Tony S K | Liu, Geoffrey | Mazieres, Julien | de Marinis, Filippo | Goto, Yasushi | Kim, Dong-Wan | Wu, Yi-Long | Jassem, Jacek | ... | Felip, Enriqueta
The Lancet Respiratory Medicine, volume 11, issue 4, pages 354-366 (2023).
10.1016/S2213-2600(22)00437-4
Cited by (76) | Cite | Source
ALK-positive lung cancer: a moving target (journal article)
Schneider, Jaime L. | Lin, Jessica J. | Shaw, Alice T.
Nature Cancer, volume 4, issue 3, pages 330-343 (2023).
10.1038/s43018-023-00515-0
Cited by (43) | Cite | Source
Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer (journal article)
Mazieres, Julien | Iadeluca, Laura | Shaw, Alice T. | Solomon, Benjamin J. | Bauer, Todd M. | de Marinis, Filippo | Felip, Enriqueta | Goto, Yasushi | Kim, Dong-Wan | Mok, Tony | ... | Liu, Geoffrey
Lung Cancer, volume 174 (2022).
10.1016/j.lungcan.2022.11.004
Cited by (15) | Cite | Source
Phase II Study of Cabozantinib in Patients With Bone Metastasis (journal article)
Choy, Edwin | Cote, Gregory M | Michaelson, M Dror | Wirth, Lori | Gainor, Justin F | Muzikansky, Alona | Sequist, Lecia V | Sullivan, Ryan J | Fidias, Panagiotis M | Shaw, Alice | Heist, Rebecca S
The Oncologist, volume 27, issue 7, pages 600-606 (2022).
10.1093/oncolo/oyac083
Cited by (2) | Cite | Source
A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib (journal article)
Schneider, Jaime L. | Muzikansky, Alona | Lin, Jessica J. | Krueger, Elizabeth A. | Lennes, Inga T. | Jacobson, Joseph O. | Cheng, Michael | Heist, Rebecca S. | Piotrowska, Zofia | Gainor, Justin F. | ... | Dagogo-Jack, Ibiayi
JTO Clinical and Research Reports, volume 3, issue 7, pages 100347- (2022).
10.1016/j.jtocrr.2022.100347
Cited by (9) | Cite | Source
Phase 3 trial of lorlatinib in treatment-naive patients (Pts) with ALK -positive advanced non–small cell lung cancer (NSCLC): Comprehensive plasma and tumor genomic analyses. (journal article)
Bearz, Alessandra | Martini, Jean-Francois | Jassem, Jacek | Kim, Sang-We | Chang, Gee-Chen | Shaw, Alice Tsang | Shepard, Deborah | Dall’O, Elisa | Polli, Anna | Thurm, Holger C. | ... | Solomon, Benjamin J.
Journal of Clinical Oncology, volume 40, issue 16_suppl, pages 9070-9070 (2022).
10.1200/JCO.2022.40.16_suppl.9070
Cited by (6) | Cite | Source
Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK + Non–small Cell Lung Cancer in the Global Phase III ALEX Trial (journal article)
Dziadziuszko, Rafal | Peters, Solange | Mok, Tony | Camidge, D. Ross | Gadgeel, Shirish M. | Ou, Sai-Hong Ignatius | Konopa, Krzysztof | Noé, Johannes | Nowicka, Malgorzata | Bordogna, Walter | ... | Shaw, Alice T.
Clinical Cancer Research, volume 28, issue 9, pages 1800-1808 (2022).
10.1158/1078-0432.CCR-21-2840
Cited by (24) | Cite | Source
Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase–Positive Lung Cancer and CNS-Specific Relapse (journal article)
Dagogo-Jack, Ibiayi | Oxnard, Geoffrey R. | Evangelist, Makenzi | Digumarthy, Subba R. | Lin, Jessica J. | Gainor, Justin F. | Murphy, John F. | Rabin, Michael S. | Heist, Rebecca S. | Muzikansky, Alona | Shaw, Alice T.
JCO Precision Oncology (2022).
10.1200/PO.21.00522
Cited by (11) | Cite | Source
Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease (journal article)
Ou, Sai-Hong I. | Solomon, Benjamin J. | Shaw, Alice T. | Gadgeel, Shirish M. | Besse, Benjamin | Soo, Ross A. | Abbattista, Antonello | Toffalorio, Francesca | Wiltshire, Robin | Bearz, Alessandra
Journal of Thoracic Oncology, volume 17, issue 4, pages 568-577 (2022).
10.1016/j.jtho.2021.12.011
Cited by (8) | Cite | Source
Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study (journal article)
Lin, J.J. | Muzikansky, A. | Kennedy, E. | Kuberski, H. | Stober, L.L. | Wanat, A.C. | Azzoli, C.G. | Lennes, I. | Sequist, L.V. | Dagogo-Jack, I. | ... | Gainor, J.F.
ESMO Open, volume 7, issue 1, pages 100342- (2022).
10.1016/j.esmoop.2021.100342
Cited by (12) | Cite | Source
Genetic landscape of patients with ALK-rearranged non–small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study (journal article)
Tan, D.S-W. | Thomas, M. | Kim, D-W. | Szpakowski, S. | Urban, P. | Mehra, R. | Chow, L.Q.M. | Sharma, S. | Solomon, B.J. | Felip, E. | ... | Shaw, A.T.
Lung Cancer, volume 163 (2022).
10.1016/j.lungcan.2021.11.007
Cited by (4) | Cite | Source
Plain Language Summary of the CROWN Study Comparing Lorlatinib with Crizotinib for People with Untreated Non-Small Cell Lung Cancer (journal article)
Solomon, Benjamin J | Bauer, Todd M | de Marinis, Filippo | Felip, Enriqueta | Goto, Yasushi | Liu, Geoffrey | Mazieres, Julien | Kim, Dong-Wan | Mok, Tony | Polli, Anna | ... | Shaw, Alice T
Future Oncology, volume 17, issue 34, pages 4649-4656 (2021).
10.2217/fon-2021-0904
Cite | Source
Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms (journal article)
Hu, Haichuan | Piotrowska, Zofia | Hare, Patricia J. | Chen, Huidong | Mulvey, Hillary E. | Mayfield, Aislinn | Noeen, Sundus | Kattermann, Krystina | Greenberg, Max | Williams, August | ... | Engelman, Jeffrey A.
Cancer Cell, volume 39, issue 11, pages 1531-1547.e10 (2021).
10.1016/j.ccell.2021.09.003
Cited by (115) | Cite | Source
1196P Pre-existing and acquired mechanisms of resistance to lorlatinib in previously treated patients (pts) with ALK+ advanced non-small cell lung cancer (NSCLC) (journal article)
Solomon, B.J. | Martini, J-F. | Bearz, A. | Tan, E.H. | Soo, R. | Besse, B. | Bauer, T.M. | Shepard, D. | Toffalorio, F. | Abbattista, A. | ... | Ou, S-H.I.
Annals of Oncology, volume 32 (2021).
10.1016/j.annonc.2021.08.1801
Cite | Source